Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that its comprehensive genomic profiling assay Northstar ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer-related deaths worldwide.

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

Prevent Cancer Foundation's 2025 Early Detection Survey showed that only about half of U.S. adults 21 years and older said ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...